Serum concentrations of soluble P-selectin glycoprotein ligand-1 are increased in patients with systemic sclerosis: Association with lower frequency of pulmonary fibrosis

Annals of the Rheumatic Diseases

Volumn 63, Issue 5, 2004, Pages 583-587

  Yanaba, K ^a,b   Takehara, K ^a   Sato, S ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

P SELECTIN GLYCOPROTEIN LIGAND 1;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VITAL CAPACITY;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PULMONARY FIBROSIS; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC;

EID: 1942500350     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.011122     Document Type: Article

References (37)

1. White B. Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am 1996;32:695-708.
2. Furst DE, Clements PJ. Hypothesis for the pathogenesis of systemic sclerosis. J Rheumatol 1997;24(suppl 48):53-7.
3. Sato S. Abnormalities of adhesion molecules and chemokines in scleroderma. Curr Opin Rheumatol 1999;11:503-7.
4. Springer TA. Traffic signals on endothdium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol 1995;57:827-72.
5. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991;67:1033-6.
6. McEver RP. Selectins. Curr Opin Immunol 1994;6:75-84.
7. Tedder TF, Li X, Steeber DA. The selectins and their ligands: adhesion molecules of the vasculature. Adv Mol Cell Biol 1999;28:65-111.
8. Springer TA, Lasky LA. Sticky sugars for selectins. Nature 1991;349:196-7.
9. Patel KD, Moore KL, Nollert MU, McEver RP. Neutrophils use both shared and distinct mechanisms to adhere to selectins under static and flow conditions. J Clin Invest 1995;96:1887-96.
10. Sako D, Chang X-J, Barone KM, Vachino G, White HM, Shaw G, et al. Expression cloning of a functional glycoprotein ligand for P-selectin. Cell 1993;75:1179-86.
11. Moore KL, Eaton SF, Lyons DE, Lichenstein HS, Cummings RD, McEver RP. The P-selectin glycoprotein ligand from human neutrophils displays sialylated, fucosylated, O-linked poly-N-acetyllactosamine. J Biol Chem 1994;269:22318-27.
12. Sako D, Comess KM, Barone KM, Camphausen RT, Cumming DA, Shaw GD. A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-selectin binding. Cell 1995;83:323.
13. Asa D, Raycroft L, Ma L, Aeed PA, Kaytes PS, Elhammer AP, et al. The P-selectin glycoprotein ligand functions as a common human leukocyte ligand for P-and E-selectins. J Biol Chem 1995;270:11662-70.
14. Guyer DA, Moore KL, Lynam EB, Schammel CMG, Rogeli S, McEver RP, et al. P-selectin glycoprotein ligand-1 (PSGL-1) is a ligand for L-selectin in neutrophil aggregation. Blood 1996;88:2415-21.
15. Dunlop LC, Skinner MP, Bendall LJ, Favaloro EJ, Castaldi PA, Gorman JJ, et al. Characterization of GMP-140 (P-selectin) as a circulating plasma protein. J Exp Med 1992;175:1147-50.
16. Takada M, Nadeau KC, Shaw GD, Marquette KA, Tilney NL The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand. J Clin Invest 1997;99:2682-90.
17. Strauss EC, Larson KA, Brenneise I, Foster CS, Larsen GR, Lee NA, et al. Soluble P-selectin glycoprotein ligand 1 inhibits ocular inflammation in a murine model of allergy. Invest Ophthalmol Vis Sci 1999;40:1336-42.
18. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
19. LeRoy EC, Krieg T, Black C, Medsger TAJ, Fleischmajer R, Rowell N, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5.
20. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
21. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-8.
22. Steen VD, Powell DL, Medsger TAJ. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988;31:196-203.
23. Sato S, Ihn H, Kikuchi K, Takehara K. Antihistone antibodies in systemic sclerosis: association with pulmonary fibrosis. Arthritis Rheum 1994;37:391-4.
24. Gruschwitz MS, Hornstein OP, von Den Driesch P. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 1995;38:184-9.
25. Ihn H, Sato S, Fujimoto M, Kikuchi K, Kadono T, Tamaki K, et al. Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: enhancement by inflammatory cytokines. Br J Rheumatol 1997;36:1270-5.
26. Ihn H, Sato S, Fujimoto M, Takehara K, Tamaki K. Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. Br J Rheumatol 1998;37:1188-92.
27. Denton CP, Bickerstaff MCM, Shiwen X, Carulli MT, Haskard DO, Dubois RM, et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 1995;34:1048-54.
28. Stratton RJ, Coghlan JG, Pearson JD, Burns A, Sweny P, Abraham DJ, et al. Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. QJM 1998;91:561-6.
29. Shimada Y, Hasegawa M, Takehara K, Sato S. Elevated serum L-selectin levels and decreased L-selectin expression on CD8(+) lymphocytes in systemic sclerosis. Clin Exp Immunol 2001;124:474-9.
30. Wakefield TW, Strieter RM, Schaub R, Myers DD, Prince MR, Wrobleski SK, et al. Venous thrombosis prophylaxis by inflammatory inhibition without anticoagulation therapy. J Vasc Surg 2000;31:309-24.
31. Hayward R, Campbell B, Shin YK, Scalia R, Lefer AM. Recombinant soluble P-selectin glycoprotein ligand-1 protects against myocardial ischemic reperfusion injury in cats. Cardiovosc Res 1999;41:65-76.
32. Lefer AM, Campbell B, Scalia R, Lefer DJ. Synergism between platelets and neutrophils in provoking cardiac dysfunction after ischemia and reperfusion: role of selectins. Circulation 1998;98:1322-8.
33. Amersi F, Dulkanchainun T, Nelson SK, Farmer DG, Kato H, Zaky J, et al. A novel iron chelator in combination with a P-selectin antagonist prevents ischemia/reperfusion injury in a rat liver model. Transplantation 2001;71:112-18.
34. Barron MK, Lake RS, Buda AJ, Tenaglia AN. Intimal hyperplasia after balloon injury is attenuated by blocking selectins. Circulation 1997;96:3587-92.
35. Bienvenu JG, Tanguay JF, Theoret JF, Kumar A, Schaub RG, Merhi Y. Recombinant soluble p-selectin glycoprotein ligand-1-Ig reduces restenosis through inhibition of platelet-neutrophil adhesion after double angioplasty in swine. Circulation 2001;103:1128-34.
36. Toombs CF, DeGraaf GL, Martin JP, Geng JG, Anderson DC, Shebuski RJ. Pretreatment with a blocking monoclonal antibody to P-selectin accelerates pharmacological thrombolysis in a primate model of arterial thrombosis. J Pharmacol Exp Ther 1995;275:941-9.
37. Kumar A, Villani MP, Patel UK, Keith JC, Schaub RG. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. Circulation 1999;99:1363-9.